Jim Simons Biotechnology

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
PBYI Puma Biotechnology, Inc.	$137M	$4.52 Million 0.01% of portfolio	1,772,413	Q3 2024 Added 1.11%
ARWR Arrowhead Pharmaceuticals, Inc.	$2.2B	$4.48 Million 0.01% of portfolio	231,300	Q3 2024 New
BCRX Biocryst Pharmaceuticals Inc	$1.42B	$4.48 Million 0.01% of portfolio	589,080	Q3 2024 Reduced 38.65%
NKTR Nektar Therapeutics	$165M	$4.33 Million 0.01% of portfolio	3,327,633	Q3 2024 Added 0.42%
SGMO Sangamo Therapeutics, Inc	$182M	$4.17 Million 0.01% of portfolio	4,852,777	Q3 2024 Added 17.6%
MNKD Mannkind Corp	$1.55B	$4.09 Million 0.01% of portfolio	651,545	Q3 2024 Added 5,012.16%
AVIR Atea Pharmaceuticals, Inc.	$263M	$4.04 Million 0.01% of portfolio	1,207,100	Q3 2024 Added 5.75%
TERN Terns Pharmaceuticals, Inc.	$169M	$4 Million 0.01% of portfolio	479,500	Q3 2024 Added 448.0%
HRTX Heron Therapeutics, Inc.	$210M	$4 Million 0.01% of portfolio	2,008,198	Q3 2024 Added 0.72%
NKTX Nkarta, Inc.	$121M	$4 Million 0.01% of portfolio	884,272	Q3 2024 Reduced 3.13%
ROIV Roivant Sciences Ltd.	$7.87B	$3.78 Million 0.01% of portfolio	327,700	Q3 2024 New
SAGE Sage Therapeutics, Inc.	$422M	$3.7 Million 0.01% of portfolio	513,300	Q3 2024 Reduced 7.25%
AUPH Aurinia Pharmaceuticals Inc.	$1.14B	$3.57 Million 0.01% of portfolio	486,700	Q3 2024 Added 141.54%
ARVN Arvinas, Inc.	$965M	$3.56 Million 0.01% of portfolio	144,400	Q3 2024 Reduced 47.57%
ERAS Erasca, Inc.	$238M	$3.52 Million 0.01% of portfolio	1,291,000	Q3 2024 Reduced 18.04%
VCEL Vericel Corp	$2.71B	$3.39 Million 0.01% of portfolio	80,300	Q3 2024 Reduced 19.54%
CNTA Centessa Pharmaceuticals PLC	$1.55B	$3.35 Million 0.01% of portfolio	209,600	Q3 2024 Added 20.67%
PRTA Prothena Corp Public LTD CO	$733M	$3.06 Million 0.0% of portfolio	182,800	Q3 2024 Reduced 44.52%
STRO Sutro Biopharma, Inc.	$106M	$2.87 Million 0.0% of portfolio	828,097	Q3 2024 Added 15.09%
RCUS Arcus Biosciences, Inc.	$950M	$2.81 Million 0.0% of portfolio	183,900	Q3 2024 Added 123.18%
VERV Verve Therapeutics, Inc.	$474M	$2.78 Million 0.0% of portfolio	574,786	Q3 2024 Added 21.14%
ALEC Alector, Inc.	$148M	$2.62 Million 0.0% of portfolio	561,750	Q3 2024 Reduced 14.24%
KRYS Krystal Biotech, Inc.	$3.97B	$2.62 Million 0.0% of portfolio	14,400	Q3 2024 New
PSTX Poseida Therapeutics, Inc.	$815M	$2.57 Million 0.0% of portfolio	897,603	Q3 2024 Added 5.0%
ACIU Ac Immune Sa	$228M	$2.44 Million 0.0% of portfolio	646,007	Q3 2024 Reduced 0.93%
SAVA Cassava Sciences Inc	$101M	$2.39 Million 0.0% of portfolio	81,100	Q3 2024 New
ANNX Annexon, Inc.	$203M	$2.38 Million 0.0% of portfolio	401,400	Q3 2024 Reduced 31.29%
NUVB Nuvation Bio Inc.	$547M	$2.37 Million 0.0% of portfolio	1,029,000	Q3 2024 Added 35.22%
MIRM Mirum Pharmaceuticals, Inc.	$1.75B	$2.36 Million 0.0% of portfolio	60,448	Q3 2024 New
CGEN Compugen LTD	$207M	$2.33 Million 0.0% of portfolio	1,287,100	Q3 2024 Reduced 0.14%
LRMR Larimar Therapeutics, Inc.	$155M	$2.32 Million 0.0% of portfolio	353,842	Q3 2024 Added 27.12%
ETNB 89bio, Inc.	$331M	$2.31 Million 0.0% of portfolio	312,024	Q3 2024 Added 11.68%
LIFE A Tyr Pharma Inc	$53.2M	$2.14 Million 0.0% of portfolio	1,149,175	Q3 2024 Reduced 11.18%
ZLAB Zai Lab LTD	$2.57B	$2.13 Million 0.0% of portfolio	88,300	Q3 2024 Added 212.97%
KURA Kura Oncology, Inc.	$534M	$2.07 Million 0.0% of portfolio	106,110	Q3 2024 Reduced 12.45%
ZNTL Zentalis Pharmaceuticals, Inc.	$127M	$2.04 Million 0.0% of portfolio	556,944	Q3 2024 Reduced 15.83%
CRVS Corvus Pharmaceuticals, Inc.	$246M	$2.04 Million 0.0% of portfolio	386,588	Q3 2024 Reduced 31.45%
ATOS Atossa Therapeutics, Inc.	$122M	$1.99 Million 0.0% of portfolio	1,310,070	Q3 2024 Reduced 15.53%
SRRK Scholar Rock Holding Corp	$2.27B	$1.87 Million 0.0% of portfolio	233,300	Q3 2024 Added 152.59%
ALLO Allogene Therapeutics, Inc.	$279M	$1.8 Million 0.0% of portfolio	642,009	Q3 2024 Reduced 63.27%
ARQT Arcutis Biotherapeutics, Inc.	$834M	$1.79 Million 0.0% of portfolio	192,099	Q3 2024 New
ACET Adicet Bio, Inc.	$36.8M	$1.77 Million 0.0% of portfolio	1,231,600	Q3 2024 Reduced 18.58%
XENE Xenon Pharmaceuticals Inc.	$2.49B	$1.73 Million 0.0% of portfolio	44,000	Q3 2024 Reduced 52.64%
GOSS Gossamer Bio, Inc.	$87.4M	$1.73 Million 0.0% of portfolio	1,744,805	Q3 2024 Reduced 14.75%
VYGR Voyager Therapeutics, Inc.	$213M	$1.63 Million 0.0% of portfolio	278,667	Q3 2024 Added 340.93%
CRDF Cardiff Oncology, Inc.	$148M	$1.61 Million 0.0% of portfolio	602,384	Q3 2024 Added 282.49%
KOD Kodiak Sciences Inc.	$417M	$1.59 Million 0.0% of portfolio	607,750	Q3 2024 Reduced 14.26%
ADAP Adaptimmune Therapeutics PLC	$96.4M	$1.57 Million 0.0% of portfolio	1,656,575	Q3 2024 Reduced 7.26%
RPTX Repare Therapeutics Inc.	$51.2M	$1.56 Million 0.0% of portfolio	453,700	Q3 2024 Reduced 1.09%
CDXC Chroma Dex Corp.	$414M	$1.55 Million 0.0% of portfolio	424,200	Q3 2024 Added 1.95%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account